AI Article Synopsis
- The Psoriatic Disease Payer Advisory Panel, held in January 2016, facilitated a collaborative discussion among patients, providers, payers, and pharmaceutical industry representatives to address the treatment needs of psoriatic patients.
- Key participants, including payers, emphasized their essential role in managing treatment access and enhancing patient outcomes throughout the dialogue.
- The outcomes of this panel aim to improve initiatives related to psoriatic disease and tackle ongoing challenges faced by all involved stakeholders.
Article Abstract
A collaborative exchange of ideas occurred at The Psoriatic Disease Payer Advisory Panel sponsored by International Dermatology Outcomes Measures (IDEOM) and The National Psoriasis Foundation (NPF) in January, 2016. Patient, provider, payer, pharmaceutical industry, IDEOM board member, and NPF leader representatives shared perspectives to address the unmet needs in the treatment of psoriatic patients. The payers who play a crucial role in controlling treatment access and improving patient outcomes played a pivotal role in the discussion. Progress made during the Payer Advisory Panel will ultimately advance psoriatic initiatives and help to address the persistent challenges of all vested stakeholders.
J Drugs Dermatol. 2016;15(5):641-644.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!